General
Preferred name
sertraline
Synonyms
SERTRALINE HYDROCHLORIDE ()
Sertraline HCl ()
CP-51974-1 HCl ()
Sertraline (HCl) ()
Zoloft ()
Sertraline (hydrochloride) ()
CP-51,974-1 ()
Lustral ()
CP-51974-1 ()
Sertraline (as hydrochloride) ()
Besitron ()
NSC-758948 ()
Aremis ()
NSC-746308 ()
Sertralina ()
Sertraline-d3 (hydrochloride) ()
Sertraline (hydrochloride) (CRM) ()
P&D ID
PD004322
CAS
79559-97-0
79617-96-2
219736-80-8
1217741-83-7
Tags
available
nuisance
drug
Approved by
FDA
First approval
1991
Drug indication
Depression
Antidepressant
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
The most common signs and symptoms associated with non-fatal sertraline overdosage were somnolence, vomiting, tachycardia, nausea, dizziness, agitation and tremor. No cases of fatal overdosage with only sertraline have been reported. Other important signs of overdose include bradycardia, bundle branch block, coma, convulsions, delirium, hallucinations, hypertension, hypotension, manic reaction, pancreatitis, QT-interval prolongation, Torsade de Pointes, serotonin syndrome, stupor, and syncope [FDA Label]. Oral LD50 of sertraline in mice and rats are 419 - 548 mg/kg and 1327 - 1591mg/kg, respectively [MSDS]. ; ; In a lifetime carcinogenicity studies on mice and rats, there was no significant evidence of sertraline-induced carcinogenic effects despite observable dose-related increases in liver adenomas in male mice receiving sertraline at 10-40 mg/kg and an increase in follicular adenomas of the thyroid in female rats receiving sertraline at 40 mg/kg [FDA Label]. There was an increase in uterine adenocarcinomas in rats receiving sertraline at 10-40 mg/kg, however this effect was not understood to be drug-related [FDA Label]. There were no signs of genotoxicity nor impairment of fertility in bacterial assays and animal studies [FDA Label].
INDICATION
For the management of major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD) with or without agoraphobia, premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD) [FDA Label]. ; ; It may be used for premature ejaculation and vascular headaches as off-label indications.
DESCRIPTION
Marketed formulations may contain sertraline hydrochloride (PubChem CID 63009).
(GtoPdb)
ABSORPTION
Following once-daily administration over the range of 50 to 200 mg for 14 days, mean peak plasma concentrations (Cmax) of sertraline occurred between 4.5 to 8.4 hours post-administration [FDA Label]. The steady-state concentrations are reached after 1 week following once-daily administration, and approximately two-fold accumulation up to steady-state concentrations is observed [FDA Label]. The single dose bioavailability of sertraline tablets is approximately equal to an equivalent dose of sertraline oral solution [FDA Label].; ; The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.
DESCRIPTION
5-HT re-uptake inhibitor
(Tocriscreen Plus)
DESCRIPTION
Selective serotonin reuptake inhibitor; antidepressant
(LOPAC library)
DESCRIPTION
5-HT re-uptake inhibitor
(Tocriscreen Total)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
7
Compound Sets
38
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
Axon Medchem Screening Library
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocriscreen Plus
Tocriscreen Total
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
81
Molecular Weight
305.07
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
2
cLogP
5.18
TPSA
12.03
Fraction CSP3
0.29
Chiral centers
2.0
Largest ring
6.0
QED
0.81
Structural alerts
1
CAD
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Selectivity
Reuptake
MOA
serotonin transporter inhibitor
5-HT Reuptake Inhibitors
selective serotonin reuptake inhibitor (SSRI)
Target
Serotonin Transporter
5-HT
SLC6A3, SLC6A4
SSRI
5-HT Receptor,Serotonin Transporter
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Member status
member
Indication
depression, obsessive compulsive disorder (OCD), panic disorders, posttraumatic stress disorder, premenstrual syndrome, social anxiety disorder
Disease Area
neurology/psychiatry, obstetrics/gynecology
Therapeutic Indication
Antidepressant
Therapeutic Class
CNS & PNS
Antidepressants
Nuisance MOA
CAD
Targets
Serotonin transporter,
Dopamine transporter
Sigma opioid receptor
Source data
